Strategy Consulting

Michelle Hoffmann, PhD
Senior Vice President

Dr. Michelle Hoffmann, joined Back Bay soon after inception in 2011 and specializes in helping both large cap and startups find growth through scientific and clinical innovation.  She has helped biopharmaceutical, medical device, diagnostic, and tools companies as well as service providers evaluate new technology platforms such as gene therapy, cell therapy, biologics, and Next Generation Sequencing.  As a result of her engagements, clients understand how to optimally apply technologies to new clinical areas and how to optimally position their advances across US and European geographies.  Michelle works side by side with the Financial Advisory team to help quantify potential valuations and advise both the Buy Side and Sell Side on transaction strategy.

Michelle joined Back Bay from Deloitte, where she led the Life Sciences arm of Deloitte Research, Deloitte’s industry think tank. Michelle was responsible for concept generation, researching and writing white papers on emerging life sciences industry topics such as the impact of Accountable Care Organizations, the mobile personal health record, medical homes and social networks.  She became a sought-after subject matter expert for Deloitte clients and public forums.

Prior to joining Deloitte Research, Michelle was a consultant in the Strategic Advisory group at Leerink Swann, a boutique health care investment bank, where she used her science and technology background to help clients understand how to value and leverage new therapies and technologies. She led projects on a diverse range of topics, including cell therapy opportunities, mapping the diagnostics landscape for colorectal and lung cancer, outlining oncology clinical strategies, determining acquisition opportunities in the next generation sequencing landscape and helping a start-up platform technology company develop its corporate strategy. Her clients included start-ups, mid-cap and top five biopharma companies.

Michelle holds a PhD in molecular and cell biology from the University of California at Berkeley and a BS in biology from Cornell. Michelle enjoys novels and spending time with her family.

Recent Posts by Michelle

Back Bay Report on Neoantigen-Based Cancer Immunotherapy

Immuno-oncology, a promise for decades, has burst forth as a clear means to advance patient care and spur research and ... Read More

Biosimilars: The Cure for Sky-High Drug Prices or a Stake in the Heart of Innovation?

Back Bay Life Science Advisors Senior Vice President, Michelle Hoffmann, wrote a piece for STAT’s “first opinion” section on the ... Read More
/ Biosimilars, Biotech, Michelle Hoffmann

US Biosimilars 2018: Opportunities and Challenges

As we start a new year, we would like to share Back Bay’s latest thought piece, US Biosimilars: Opportunities and Challenges.  Researched ... Read More
Share this: